All bacillus Calmette-Guérin (BCG) strains are equal, but some BCG strains are more equal than others

European Urology

Volumn 66, Issue 4, 2014, Pages 689-691

  Noon, Aidan P ^a   Kulkarni, Girish S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MITOMYCIN; BCG CONNAUGHT;

BACTERIAL STRAIN; BLADDER CARCINOMA; GENETIC DIFFERENCE; HUMAN; MAINTENANCE THERAPY; MYCOBACTERIUM BOVIS BCG; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSITIONAL CELL CARCINOMA; TUBERCULOSIS; BACTERIAL COLONIZATION; BCG VACCINATION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PROTOCOL; COLONY FORMING UNIT; COMPARATIVE EFFECTIVENESS; EDITORIAL; HIGH RISK PATIENT; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; UROTHELIAL BLADDER CARCINOMA; ANIMAL; CARCINOMA, TRANSITIONAL CELL; FEMALE; MALE; MORTALITY; URINARY BLADDER NEOPLASMS;

ANIMALS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; URINARY BLADDER NEOPLASMS;

EID: 84922559610     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.04.008     Document Type: Editorial

References (11)

1. A. Morales, D. Eidinger, and A.W. Bruce Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors J Urol 116 1976 180 183
2. A.V. Kaisary Intravesical BCG therapy in the management of multiple superficial bladder carcinoma. Comparison between Glaxo and Pasteur strains Br J Urol 59 1987 554 558
3. N. Ikeda, I. Honda, I. Yano, A. Koyama, and I. Toida Bacillus calmette-guerin Tokyo172 substrain for superficial bladder cancer: characterization and antitumor effect J Urol 173 2005 1507 1512
4. C. Gan, H. Mostafid, M.S. Khan, and D.J. Lewis BCG immunotherapy for bladder cancer - the effects of substrain differences Nat Rev Urol 10 2013 580 588
5. A.P. Noon, and J.W. Catto Bladder cancer in 2012: challenging current paradigms Nat Rev Urol 10 2013 67 68
6. C.A. Rentsch, F.D. Birkhäuser, and C. Biot et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy Eur Urol 66 2014 677 688
7. P.D. Vegt, J.A. Witjes, W.P. Witjes, W.H. Doesburg, F.M. Debruyne, and A.P. van der Meijden A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder J Urol 153 1995 929 933
8. G.J. Fellows, M.K. Parmar, K.M. Grigor, R.R. Hall, M.R. Heal, and D.M. Wallace Marker tumour response to Evans and Pasteur bacille Calmette-Guerin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party) Br J Urol 73 1994 639 644
9. A. Mukherjee, R. Persad, and P.J. Smith Intravesical BCG treatment for superficial bladder cancer: long-term results using two different strains of BCG Br J Urol 69 1992 147 150
10. T. Inamoto, T. Ubai, T. Nishida, Y. Fujisue, Y. Katsuoka, and H. Azuma Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guerin prophylaxis in nonmuscle invasive bladder cancer: results of a randomized prospective comparison Urol Ann 5 2013 7 12
11. A. Sengiku, M. Ito, Y. Miyazaki, H. Sawazaki, T. Takahashi, and K. Ogura A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer J Urol 190 2013 50 54